Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
markets
June 2025 US stock market outlook: Has the storm passed?
Be wary of the recent complacency; there’s turbulent water ahead before the skies clear.
markets
US stock market outlook: Where we see opportunities in Q2
A bear market in AI stocks leads to more attractive valuations.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.80 | 86.80 | 1.00% |
| CAC 40 | 7,633.07 | 95.50 | 1.27% |
| DAX 40 | 23,721.93 | 452.92 | 1.95% |
| Dow JONES (US) | 42,581.78 | 374.96 | 0.89% |
| FTSE 100 | 8,787.51 | 29.47 | 0.34% |
| HKSE | 24,177.07 | 487.94 | 2.06% |
| NASDAQ | 19,630.97 | 183.56 | 0.94% |
| Nikkei 225 | 38,790.56 | 436.47 | 1.14% |
| NZX 50 Index | 12,467.48 | 65.17 | -0.52% |
| S&P 500 | 6,025.17 | 57.33 | 0.96% |
| S&P/ASX 200 | 8,555.50 | 80.60 | 0.95% |
| SSE Composite Index | 3,420.57 | 38.98 | 1.15% |